ReviewCommunications biology2026
Mesenchymal stem cell-derived extracellular matrix for musculoskeletal tissue regeneration.
Review in Communications biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Reconstructing protein conformations to activate follicular enzyme-nutrient reservoirs for reversing follicle aging.Bioactive materials · 2026Article
- AI for bioactive materials: From material design to biological applications.Bioactive materials · 2026Review
- Equine mesenchymal stromal cells dual-primed with TGF-β1 and IL-1β or TNF-α improve epithelial healing.Research square · 2026Article
- Article
- Collagen-Based Microspheres for Biomedical Applications in Drug Delivery and Tissue Engineering.Biomimetics (Basel, Switzerland) · 2026Review
- Biomimetic Scaffolds and Extracellular Matrix-Based Strategies for Myofiber Regeneration in Volumetric Muscle Loss.Drug design, development and therapy · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Mesenchymal stem cell-derived extracellular matrix (mECM) is increasingly recognized in tissue regeneration due to its high biocompatibility, controllability, and customizability. In musculoskeletal diseases, mECM provides a 3D scaffold mimicking the natural cellular environment and contains bioactive components regulating cell behavior and fate to promote tissue regeneration and repair. This review summarizes the preparation methods and composition of mECM, its effects on regulating cell behavior, and its applications in bone, cartilage, muscle, nerve, and blood vessel repair. It also analyzes the potential mechanisms of mECM's effects and identifies key challenges to be addressed prior to clinical translation, outlining future development directions.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.